Clinical Trial Finder

Inclusion Criteria:

• - Patients with the diagnosis of neuroblastoma must meet both of the following criteria: - Diagnosis confirmed by histological assessment by MSKCC Department of pathology or by the presence of BM metastases PLUS elevated urinary catecholamines.

• - Relapsed or refractory stage 4 disease or relapsed or refractory stage MYCN-amplified 2B or 3 disease.

• - Patients with tumors other than neuroblastoma must meet both the following criteria: - Have one of the following diagnoses (these tumors are known to express GD2 on cell surface): - Melanoma.

• - Osteogenic sarcoma.

• - Leiomyosarcoma.

• - Ewing sarcoma.

• - Liposarcoma.

• - Fibrosarcoma.

• - Malignant fibrous histiocytoma.

• - Spindle cell sarcoma.

• - Small cell lung cancer.

• - Medulloblastoma metastatic to extracranial sites.

• - Paraganglioma.

• - Have refractory or relapsed or metastatic disease.

• - Patients with solid tumors with diagnoses OTHER than neuroblastoma or those listed above will be eligible if they meet both of the following criteria: - Immunohistochemical demonstration of GD2 expression on cell surface (Tumor assessment by immunohistochemistry is required for this group of patients) - Have refractory or relapsed disease or metastatic disease.

All patients must have measurable or evaluable disease.

• - Age 3-90 years.

• - Prior treatment with anti-GD2 monoclonal antibody is permitted only if human anti-human antibody titer is ≤1300 assay developed by Dr.

Nai-Kong Cheung.

• - Negative serum pregnancy test in women of childbearing potential.

• - Women of child-bearing potential must be willing to practice an effective method of birth control while on study.

• - Signed informed consent indicating awareness of the investigational nature of this study.

Exclusion Criteria:

• - Existing major organ dysfunction > grade 2, with the exception of myelosuppression (neutrophil count > or = 500/μl and platelet count > or = 25,000/μl are acceptable) and hearing loss.

• - Acute life threatening infection.

• - Requirement for sedation for PET/CT scans.

• - Pregnant women or women who are breast-feeding.

• - Inability to comply with protocol requirements.

• - Hypersensitivity to potassium iodide or Lugols products.

• - Prior development of positive human antimouse antibody response (HAMA) or human antihuman antibody response (HAHA) - Positive human anti-hu3F8 antibody titer.

Arms

Experimental: PET Imaging using 124I-Humanized 3F8

124I-hu3F8 at a dose of 3mCi/m2 (with a maximum dose of 5mCi) will be injected IV. 124I-hu3F8 PET/CT scans will be performed at approximately 2-4 hours, 18-26hours, 48-72 hours and 96-144 hours after injection of 124I-hu3F8. A low dose CT scan will be obtained with each PET scans. PET/CT scan images will be analyzed to determine biodistribution of 124I-hu3F8 and to determine dosimetry to organs and sites of disease. Comparison of tumor targeting and tumor dosimetry will be made between the two cohorts of patients: (a) NB and (b) other solid tumors. Blood will be drawn where feasible at multiple time points: approximately 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120h-144h after injection of 124I-hu3F8 and radioactivity measured to determine pharmacokinetics of 124I-hu3F8.

Interventions

Biological: - 124I-Humanized 3F8